ReviewJournal of neurovirology2021
Potential mechanisms of cerebrovascular diseases in COVID-19 patients.
Review in Journal of neurovirology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mechanisms of pediatric ischemic strokes in COVID-19: a systematic review.Frontiers in stroke · 2023Pooled it
- Physical activity during COVID-19 pandemic: A 5-year retrospect.Sports medicine and health science · 2025Review
- The neutrophil extracellular traps in neurological diseases: an update.Clinical and experimental immunology · 2024Review
- New Directions in Infection-Associated Ischemic Stroke.Journal of clinical neurology (Seoul, Korea) · 2024Review
- Neurovascular coupling impairment as a mechanism for cognitive deficits in COVID-19.Brain communications · 2024Review
- One-year post-acute COVID-19 syndrome and mortality in South Korea: a nationwide matched cohort study using claims data.Frontiers in public health · 2024Article
- Neurological manifestations of SARS-CoV-2: complexity, mechanism and associated disorders.European journal of medical research · 2023Review
- Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease.Journal of personalized medicine · 2023Review
- Recombinant tissue plasminogen activator (rTPA) management for first onset acute ischemic stroke with covid -19 and non-covid -19 patients.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2023Article
- Pathophysiological mechanisms of thrombosis in acute and long COVID-19.Frontiers in immunology · 2022Review
- NETosis and Neutrophil Extracellular Traps in COVID-19: Immunothrombosis and Beyond.Frontiers in immunology · 2022Review
- Periodontitis-Derived Dark-NETs in Severe Covid-19.Frontiers in immunology · 2022Review
- Oxidative Stress and Hyper-Inflammation as Major Drivers of Severe COVID-19 and Long COVID: Implications for the Benefit of High-Dose Intravenous Vitamin C.Frontiers in pharmacology · 2022Review
- Alterations in Tryptophan Metabolism Affect Vascular Functions: Connected to Ageing Population Vulnerability to COVID-19 Infection?International journal of tryptophan research : IJTR · 2022Article
- Patients with COVID-19: in the dark-NETs of neutrophils.Cell death and differentiation · 2021Review
- Diagnostic and Therapeutic Challenges of Cerebral Venous Thrombosis in SARS-CoV-2 Infection: A Case Report and Review of Literature.Clinics and practice · 2021Article
- Arterial stiffness and COVID-19: A bidirectional cause-effect relationship.Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
- Case Report: Cerebrovascular Events Associated With Bacterial and SARS-CoV-2 Infections in an Adolescent.Frontiers in neurology · 2021Article
- Computed tomography features of cerebrovascular complications in intensive care unit patients with severe COVID-19.Radiologia brasileiraArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the outbreak of coronavirus disease 2019 (COVID-19) in 2019, it is gaining worldwide attention at the moment. Apart from respiratory manifestations, neurological dysfunction in COVID-19 patients, especially the occurrence of cerebrovascular diseases (CVD), has been intensively investigated. In this review, the effects of COVID-19 infection on CVD were summarized as follows: (I) angiotensin-converting enzyme 2 (ACE2) may be involved in the attack on vascular endothelial cells by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), leading to endothelial damage and increased subintimal inflammation, which are followed by hemorrhage or thrombosis; (II) SARS-CoV-2 could alter the expression/activity of ACE2, consequently resulting in the disruption of renin-angiotensin system which is associated with the occurrence and progression of atherosclerosis; (III) upregulation of neutrophil extracellular traps has been detected in COVID-19 patients, which is closely associated with immunothrombosis; (IV) the inflammatory cascade induced by SARS-CoV-2 often leads to hypercoagulability and promotes the formation and progress of atherosclerosis; (V) antiphospholipid antibodies are also detected in plasma of some severe cases, which aggravate the thrombosis through the formation of immune complexes; (VI) hyperglycemia in COVID-19 patients may trigger CVD by increasing oxidative stress and blood viscosity; (VII) the COVID-19 outbreak is a global emergency and causes psychological stress, which could be a potential risk factor of CVD as coagulation, and fibrinolysis may be affected. In this review, we aimed to further our understanding of CVD-associated COVID-19 infection, which could improve the therapeutic outcomes of patients. Personalized treatments should be offered to COVID-19 patients at greater risk for stroke in future clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.